Neurogene Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Net Income	-36.32	-55.19	-60.69	-33.28	-69.44	Upgrade
Depreciation & Amortization	3.96	3.81	2.28	1.82	0.53	Upgrade
Share-Based Compensation	1.42	1.25	11.56	5.62	7.68	Upgrade
Other Operating Activities	-20.48	-2.7	-0.7	1.26	45.84	Upgrade
Operating Cash Flow	-51.42	-52.82	-47.56	-24.58	-15.39	Upgrade
Capital Expenditures	-0.32	-2.23	-3.26	-2.22	-0.88	Upgrade
Acquisitions	20.96	0	0	0	0.19	Upgrade
Change in Investments	5	0	0	0	0	Upgrade
Investing Cash Flow	25.64	-2.23	-3.26	-2.22	-0.69	Upgrade
Share Issuance / Repurchase	92.51	0.07	0.78	77.54	82.6	Upgrade
Debt Issued / Paid	-0.03	-0	-0.05	-0.05	-0.01	Upgrade
Other Financing Activities	-	66.46	-	-0.36	-0.35	Upgrade
Financing Cash Flow	92.48	66.53	0.73	77.14	82.24	Upgrade
Exchange Rate Effect	0	0	0	0	0.01	Upgrade
Net Cash Flow	66.7	11.48	-50.09	50.34	66.17	Upgrade
Free Cash Flow	-51.74	-55.05	-50.82	-26.79	-16.27	Upgrade
Free Cash Flow Per Share	-105.20	-139.54	-18.47	-10.34	-12.04	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).